Skip to content
10-Q

Quarterly Report

Design Therapeutics, Inc. DSGN

0001193125-26-187063

← back to feed
Filed
Apr 28, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 23, 2026 62.46M sh
Shares Diluted Q1 2026 · Mar 31, 2026 61.43M sh
Shares Diluted Q1 2026 · Mar 31, 2025 56.76M sh
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $72K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$16.43M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$16.79M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $12.77M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $16.86M
Stockholders Equity Q1 2026 · Mar 31, 2026 $218.05M
Stockholders Equity Q1 2026 · Dec 31, 2025 $212.5M
Stockholders Equity Q1 2026 · Mar 31, 2025 $227.92M
Stockholders Equity Q1 2026 · Dec 31, 2024 $242.1M
Current Liabilities Q1 2026 · Mar 31, 2026 $10.19M
Current Liabilities Q1 2026 · Dec 31, 2025 $13.06M
Total Liabilities Q1 2026 · Mar 31, 2026 $12.39M
Total Liabilities Q1 2026 · Dec 31, 2025 $13.7M
Current Assets Q1 2026 · Mar 31, 2026 $227.05M
Current Assets Q1 2026 · Dec 31, 2025 $223.78M
Total Assets Q1 2026 · Mar 31, 2026 $230.44M
Total Assets Q1 2026 · Dec 31, 2025 $226.2M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.29
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.31
Eps Basic Q1 2026 · Mar 31, 2026 −$0.29
Eps Basic Q1 2026 · Mar 31, 2025 −$0.31
Sga Expense Q1 2026 · Mar 31, 2026 $5.33M
Sga Expense Q1 2026 · Mar 31, 2025 $5.04M
Rd Expense Q1 2026 · Mar 31, 2026 $14.38M
Rd Expense Q1 2026 · Mar 31, 2025 $15.38M
Net Income Q1 2026 · Mar 31, 2026 −$17.64M
Net Income Q1 2026 · Mar 31, 2025 −$17.72M
Operating Income Q1 2026 · Mar 31, 2026 −$19.71M
Operating Income Q1 2026 · Mar 31, 2025 −$20.42M